Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits
Top Cited Papers
Open Access
- 11 November 2005
- Vol. 331 (7526), 1169
- https://doi.org/10.1136/bmj.38623.768588.47
Abstract
Objectives To quantify and compare potential benefits (subjective reports of sleep variables) and risks (adverse events and morning-after psychomotor impairment) of short term treatment with sedative hypnotics in older people with insomnia. Data sources Medline, Embase, the Cochrane clinical trials database, PubMed, and PsychLit, 1966 to 2003; bibliographies of published reviews and meta-analyses; manufacturers of newer sedative hypnotics (zaleplon, zolpidem, zopiclone) regarding unpublished studies. Selection criteria Randomised controlled trials of any pharmacological treatment for insomnia for at least five consecutive nights in people aged 60 or over with insomnia and otherwise free of psychiatric or psychological disorders. Results 24 studies (involving 2417 participants) with extractable data met inclusion and exclusion criteria. Sleep quality improved (effect size 0.14, P < 0.05), total sleep time increased (mean 25.2 minutes, P < 0.001), and the number of night time awakenings decreased (0.63, P < 0.001) with sedative use compared with placebo. Adverse events were more common with sedatives than with placebo: adverse cognitive events were 4.78 times more common (95% confidence interval 1.47 to 15.47, P < 0.01); adverse psychomotor events were 2.61 times more common (1.12 to 6.09, P > 0.05), and reports of daytime fatigue were 3.82 times more common (1.88 to 7.80, P < 0.001) in people using any sedative compared with placebo. Conclusions Improvements in sleep with sedative use are statistically significant, but the magnitude of effect is small. The increased risk of adverse events is statistically significant and potentially clinically relevant in older people at risk of falls and cognitive impairment. In people over 60, the benefits of these drugs may not justify the increased risk, particularly if the patient has additional risk factors for cognitive or psychomotor adverse events.Keywords
This publication has 54 references indexed in Scilit:
- Factors influencing prescription of CNS medications in different elderly populationsPharmacoepidemiology and Drug Safety, 2003
- Zaleplon, A Novel Nonbenzodiazepine Hypnotic, Effectively Treats Insomnia in Elderly Patients Without Causing Rebound EffectsThe Primary Care Companion For CNS Disorders, 1999
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Double-blind comparison of zopiclone and flunitrazepam in elderly insomniacs with special focus on residual effectsCurrent Medical Research and Opinion, 1995
- Sensitivity to Triazolam in the ElderlyThe New England Journal of Medicine, 1991
- Clinical Safety of Flurazepam and Midazolam duringJournal of Clinical Psychopharmacology, 1990
- A double-blind comparison of two lormetazepam doses in elderly insomniacsCurrent Medical Research and Opinion, 1988
- A COMPARATIVE STUDY OF LORMETAZEPAM AND CHLORMETHIAZOLE IN ELDERLY IN-PATIENTSAge and Ageing, 1987
- Clinical and psychometric evaluation of two doses of loprazolam and placebo in geriatric patientsCurrent Medical Research and Opinion, 1986
- ASPECTS OF SHORT-TERM USE OF TWO BENZODIAZEPINE HYPNOTICS IN THE ELDERLYAge and Ageing, 1982